Malignant Mesothelioma Therapeutic Market

Key data points: Market size in 2027 = $400.8 million and 2035 = $804.5 million, growth forecast = 7.1% annually for the next 8 years. Scroll below to get more insights. This market report covers trends, opportunities and forecasts in malignant mesothelioma therapeutic market to 2035 by type (pemetrexed, cisplatin, immunotherapy agents, and others), application (pleural mesothelioma, peritoneal mesothelioma, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World) Malignant Mesothelioma Therapeutic Market The future of the global malignant mesothelioma therapeutic market looks promising with opportunities in the pleural mesothelioma and peritoneal mesothelioma markets. The global malignant mesothelioma therapeutic market is expected to reach an estimated $804.5 million by 2035 from $400.8 million in 2027 with a CAGR of 7.1% from 2027 to 2035. The major drivers for this market are the increasing incidence of malignant mesothelioma, the rising demand for advanced treatment options, and the growing awareness of occupational health risks. • Lucintel forecasts that, within the type category, immunotherapy agents is expected to witness the highest growth over the forecast period due to better survival rates with immunotherapy. • Within the application category, pleural mesothelioma is expected to witness higher growth over the forecast period due to more mesothelioma caused by exposure to asbestos. • In terms of regions, APAC is expected to witness the highest growth over the forecast period due to more asbestos exposure in the workplace and increase in cancer cases. Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below. Emerging Trends in Malignant Mesothelioma Therapeutic Market Malignant mesothelioma therapy is anticipated to evolve beyond traditional chemotherapy to include various other modalities including biological response modifier (BRM) based immunotherapies and combination therapies between 2025 and 2027. Lucintel’s assessment is concurrent with the industry trend toward goal-directed and flexible sequencing of therapies focused on unresectable malignancies. • Immunotherapies: The mainstay of therapy for unresectable malignant mesothelioma is expected to be a checkpoint inhibitor, potentially combined with other therapies, for the next several years. It is expected that oncologists will prefer to use immunotherapies over other modalities to achieve a clinical benefit, even if the duration of that clinical benefit is unknown. • Combination Therapies: As combination therapies become the standard of care and improve clinical outcomes, greater emphasis will be placed on proper sequencing of therapies and the economic value of the therapy. • Biomarker Guided Approaches: In 2025, there are anticipated to be several clinical trials evaluating various biomarkers in mesothelioma. The results of these trials are expected to improve the understanding of patient selection for clinical trials and help focus the development of therapies for mesothelioma. • Antibody and Cell Therapies: Anticipate Phase I/II data on multiple antibody drug conjugates, vaccines, and cell therapies directed against mesothelin in 2025. The high global case load (approximately 30,000 cases/year) is expected to stimulate development of new modalities to address mesothelioma. In the coming years, there will be increased focus on the development of specialized and efficient therapies. • Thoracic Oncology Specialization: It is anticipated that by 2027 the majority of mesothelioma-related therapies will be available at thoracic oncology facilities. These centres will have the ability to perform surgical excision and provide other systemic modalities. Increased specialization is expected to facilitate improved diagnosis and concentration of therapies. High unmet need and potentially high-cost therapies warrant continued interest from the pharmaceutical and biotech industry. First generation therapies are expected to be immunotherapies. Survival benefit of targeted therapies is expected to drive the field in the coming years. Beyond oncology, first generation therapies are expected to treat other indications. Recent Developments in the Malignant Mesothelioma Therapeutic Market Malignant mesothelioma will likely have greater therapeutic options in the 2025-2027 timeframe, but widespread commercialization will be limited due to the low prevalence of the disease and the fact that it is usually diagnosed at an advanced stage. Other forms of treatment, particularly immunotherapy and antibody drug conjugates, are also being explored and funded. According to Lucintel, the successful completion of clinical trials will be the largest determinant of the growth potential of these products. • Other Forms of Combination Immunotherapy: Besides ipilimumab and nivolumab, other checkpoint inhibitors are being studied in the context of mesothelioma. These agents are being advanced for use in later line therapies. The data will need to demonstrate improved survival to justify their use and address the concerns around the toxicities of immunotherapy. • Development of Other Mesothelin-targeted Therapies: A number of companies are focused on the development of mesothelin-targeted antibody drug conjugates. Other phase I studies of T cell and mesothelin-targeted CAR-T therapies will also be initiated in the next few years. • Development of Other Inhibitors: There are a number of other potential targets and inhibitors of mesothelioma being studied including the WNT pathway. Positive outcomes from these studies could lead to the development of premium products. • Biomarker-based Trial Design: Enrolment for multiple studies is being founded on the presence of BAP1 deletion or loss of function; mesothelin expression; and/or tumour mutational burden. One study initiated in September 2025, has added 12 sites and is currently enrolling. The use of biomarkers to improve the likelihood of regulatory approval should improve the overall trial-to-regulatory-approval-to-market time and price. • Manufacturing & Access: There is a focus on manufacturing a biologic in a way that supports commercialization and the readiness of a companion diagnostic. One regional oncology network, in February 2026, announced the ability to treat 200 additional cancer patients each year. The amount of potential sites supported, and the reliability of the supply of biologics, will impact market penetration. There will be numerous sources of income within the oncology space from improved patient selection and the use of simultaneous, combination sequencing, and therapies integrated within the current oncology processes and workflows. Positive outcomes from these advances should also improve the success of mesothelin-based therapies and increase investment. Strategic Growth Opportunities in the Malignant Mesothelioma Therapeutic Market from 2024 To 2026: Better survival data leads to indication expansion. Simultaneously, other immuno-oncology therapies are expected to occupy earlier lines of therapy. Additionally, the use of biomarker testing is anticipated to improve. Lastly, with rising costs of cancer therapies, cheaper alternatives may be sought after. Lucintel expects evidence-based platforms will dominate the malignant mesothelioma market. • Biomarker-based Therapies: The FDA's framework in March 2025 allowed for tissue-agnostic pembrolizumab for cancers containing dMMR or MSI-H. Other mesothelioma frameworks or approvals may occur in the next 3-5 years. • Combination Immunotherapies: The Checkmate 743 study reported an overall survival of 23.2% at 3 years with the combination of nivolumab and ipilimumab. Other combination therapies may be approved in the near future. • First Line/early Use of Immunotherapies: The FDA granted Breakthrough Designation in January 2025 to a combination of pembrolizumab and chemotherapy for mesothelioma. Other first line or early combination therapies are expected to be studied. • Specialist Regional Expansion: Recent European health assessments estimated that about 4,000 new mesothelioma cases occur in Europe each year. Improving mesothelioma referral and diagnostic pathways as well as access to treatment within specialist cancer networks is likely to benefit patients in underserved regions. • Lower-cost Delivery Models: Guidance from the April 2025 ASCO Annual Meeting reiterated the importance of providing outpatient cancer care. Over the next 5 years, it is likely that providing an oncology service in the community through infusion or other services, and managing patients remotely will help reduce the cost of providing oncology services. It is likely that in the next 5 years, the mesothelioma market will continue to evolve and rely less on a single blockbuster therapy. Expansion of other therapies, such as combinations of immunotherapies and the use of biomarkers to define patient eligibility for clinical trials will allow a greater number of patients to be enrolled in and to benefit from clinical trials. With the cost of providing these services likely to be high, and the patient population small, evidence of the effectiveness of a therapy, as well as an economic case for providing the therapy, will help healthcare payers make a case to patients for funding. Malignant Mesothelioma Therapeutic Market Drivers and Challenges Market growth for mesothelioma therapeutics is largely attributable to advancements in the fields of medicine and science. Clinical trials and the opening of mesothelioma treatment centres drive the adoption of new therapies. Further, evolving reimbursement policies facilitate greater access to mesothelioma therapies. The report authored by Lucintel acknowledges the challenges facing the market, but identifies even greater opportunity. The factors responsible for driving this market include: • Increased Recognition: Asbestos exposure and resulting mesothelioma diagnoses have led to greater public awareness of the disease and improved the ability to diagnose the condition. The World Health Organization has projected that 30,000 or more individuals will be diagnosed with mesothelioma by 2025. Improved case recognition will lead to greater treatment adoption. While treatment centres in several countries have reported high patient volumes, underserved areas remain. • Innovations in Immunotherapy: In 2025, combination therapies utilizing two checkpoint inhibitors remained at the trial stage. The next several years will likely see an increased preference toward therapies utilizing immunotherapy. Additionally, combination therapies and other innovative approaches to treatment will likely strengthen the market. • Advances in Pharmaceutical Research: In addition to various studies on different types of cancer, April 2025, witnessed different phases of clinical trials for various anti-mesothelioma therapies. With growing interest and commitment in cancer research, it is expected that, within the next 3 to 5 years, the opportunities available for the selection of treatment options for mesothelioma patients will increase. • Encouraging Regulatory Environment: Oncology is one of the major focus areas of research and development, especially in the area of rare cancers. One of the positive developments in the field, during the month of May, 2025, was that various regulatory agencies expressed interest in facilitating the introduction of new medications for cancers affecting less than 200,000 persons in the U.S. This includes efforts to encourage, support and ease the process of product development. • Focus on Cancer Care Infrastructure: May 2025 also witnessed positive development in the field of cancer care, as different countries initiated the establishment of research and diagnostic centres with advanced facilities for genomic testing. This is expected to increase the overall diagnostic capacity, especially in identifying cancers at advanced/later stages. The challenges facing this market include: • Rarity of Mesothelioma Cases: One of the key market challenges is that mesothelioma is a very rare cancer. Because of this, even the best and the most advanced clinical trials are often limited to a few dozens of patients. This will continue to be the case for the next 5 years. • High Treatment Costs: Combination therapies and diagnostics, as well as prolonged use of palliative or supportive care, increase financial burden on patients and healthcare systems. In 2025, the cost of some types of advanced cancer treatments in developed markets was reported to be in excess of $100,000. In the short to medium term, anticipate restrictions on reimbursement to discourage use of such therapies in emerging markets. • Limited Therapeutic Benefits: Lack of adequate screening and diagnosis, and the development of treatment resistant cancers result in high rates of morbidity and mortality. Therapeutic benefits are further limited by heterogeneity of tumors. As of September 2025, several studies and publications reported median survival of patients with advanced cancers in terms of months. The need for improved diagnostics, combined with ongoing clinical research and innovative regulatory pathways, offers the potential for improvement in outcomes for patients with malignant mesothelioma. Several market barriers will need to be concurrently addressed for Mesothelioma treatment to be more widely available. Given the high cost of treatment and expected benefits in terms of improved survival, the market will experience gradual growth. Innovations in the field of oncology will likely favour developed countries first. List of Malignant Mesothelioma Therapeutic Market Companies Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies malignant mesothelioma therapeutic market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the malignant mesothelioma therapeutic market companies profiled in this report include- • Eli Lilly • Teva • Sanofi • Bristol-Myers Squibb • Pfizer • Roche • Merck • Ono Pharmaceutical • Mylan • Fresenius Kabi Malignant Mesothelioma Therapeutic Market by Segment The study includes a forecast for the global malignant mesothelioma therapeutic market by type, application, and region. Malignant Mesothelioma Therapeutic Market by Type [Value ($M) from 2019 to 2035]: • Pemetrexed • Cisplatin • Immunotherapy Agents • Others Malignant Mesothelioma Therapeutic Market by Application [Value ($M) from 2019 to 2035]: • Pleural Mesothelioma • Peritoneal Mesothelioma • Others Malignant Mesothelioma Therapeutic Market by Region [Value ($M) from 2019 to 2035]: • North America • Europe • Asia Pacific • The Rest of the World Country Wise Outlook for the Malignant Mesothelioma Therapeutic Market There are ongoing developments within the field of mesothelioma due to advances in Immuno-Oncology and Oncology as a whole. This has led to favourable regulations for the development of Oncology products. Additionally, larger and multinational clinical trials are being undertaken. It is expected that between 2025 and 2027, combination therapies will be the main focus for product development and that advancement in the field will be driven by strategic alliances and partnerships. According to Lucintel, differentiation in the field will be based on the extent of clinical evidence. • United States: Nivolumab and ipilimumab, combined, are the only first line, immunotherapy products, approved by the Food and Drug Administration (FDA), for the treatment of malignant pleural mesothelioma. The CheckMate-743 study, which assessed the combination, reported a five-year overall survival rate of 41% (September 2025). The continued support by the U.S. government for the development of rare cancer therapies, is anticipated to increase the use of and demand for immunotherapies and companion diagnostics. • China: The Chinese National Medical Products Administration (formerly known as the China Food and Drug Administration) has established several pathways to expedite review of oncology products, and several domestic companies are conducting clinical trials for mesothelioma using antibody and combination products. One 2025 registry clinical trial listed a study to assess a mesothelioma product, which, if approved, would help fulfil the growing demand for these therapies in China. • Germany: Situated within the EU clinical trial framework, Germany has specialized centres and facilities that enhance its capabilities for clinical trials. University Hospital Heidelberg is one of several such centres. A University of Heidelberg 2025 mesothelioma clinical trial will evaluate up to 60 patients. Additionally, German law facilitates the conduct of clinical trials. These factors should enable Germany to play a more prominent role in the development and commercialization of oncology therapies within the EU. • India: The Department of Biotechnology of India and major oncology hospitals of the country facilitated investigator-initiated research in cancer immunotherapy. Simultaneously, the generic and biosimilar drug industry in the country enabled broader access to cancer therapies. A 2025 mesothelioma trial with 50 subjects has also been initiated. Lower costs of production and larger infrastructure of hospitals in India and other South Asian countries will facilitate greater competition in price and access of therapies within the region. • Japan: The Pharmaceuticals and Medical Devices Agency of Japan, and other regulatory agencies of the country, continued to facilitate the approval of rare disease therapies. Japanese centres participated in international mesothelioma immunotherapy trials. A 2025 mesothelioma trial will be conducted at 30 sites in Japan. Regulatory and policy changes will facilitate the introduction of therapies developed outside Japan to the country. Features of the Global Malignant Mesothelioma Therapeutic Market Market Size Estimates: malignant mesothelioma therapeutic market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions. Segmentation Analysis: malignant mesothelioma therapeutic market size by type, application, and region in terms of value ($B). Regional Analysis: malignant mesothelioma therapeutic market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the malignant mesothelioma therapeutic market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the malignant mesothelioma therapeutic market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model. If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more. This report answers following 11 key questions: Q.1. What are some of the most promising, high-growth opportunities for the malignant mesothelioma therapeutic market by type (pemetrexed, cisplatin, immunotherapy agents, and others), application (pleural mesothelioma, peritoneal mesothelioma, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)? Q.2. Which segments will grow at a faster pace and why? Q.3. Which region will grow at a faster pace and why? Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market? Q.5. What are the business risks and competitive threats in this market? Q.6. What are the emerging trends in this market and the reasons behind them? Q.7. What are some of the changing demands of customers in the market? Q.8. What are the new developments in the market? Which companies are leading these developments? Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth? Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution? Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?